PYC Therapeutics Limited
PYC
Rank in Stocks
#9736
PYC Therapeutics Limited, a drug-development company, engages in the discovery... PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Share Price
$1.37
Last synced: 2026-11-10
Market Cap
$799.09M
Change (1 day)
0.38%
Change (1 year)
76.49%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade PYC Therapeutics Limited (PYC)
Category
Healthcare
EPS for PYC Therapeutics Limited (PYC)
EPS as of June 2026 TTM: $-0.04
According to PYC Therapeutics Limited's latest financial reports, its current EPS (TTM) is $-0.04. At the end of 2025 the company had an EPS of $-0.07, a decrease compared to its 2024 EPS of $-0.01.
EPS history for PYC Therapeutics Limited from 2005 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.04 | -40.43% |
| 2025 | $-0.07 | 928.13% |
| 2024 | $-0.01 | 36.17% |
| 2023 | 0.00 | 56.67% |
| 2022 | 0.00 | -30.23% |
| 2021 | 0.00 | 152.94% |
| 2020 | 0.00 | 54.55% |
| 2019 | 0.00 | -54.17% |
| 2018 | 0.00 | 380.00% |
| 2017 | 0.00 | -66.67% |
| 2016 | 0.00 | 87.50% |
| 2015 | 0.00 | -27.27% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | -21.43% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 7.69% |
| 2009 | 0.00 | -13.33% |
| 2008 | 0.00 | 25.00% |
| 2007 | 0.00 | 20.00% |
| 2006 | 0.00 | 100.00% |
| 2005 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -37,653.96% |
US
|
|
| $-7.07 | 16,854.44% |
US
|
|
| $-5.29 | 12,585.85% |
AU
|
|
| $12.88 | -30,987.53% |
BE
|
|
| $21.56 | -51,802.64% |
NL
|
Questions about PYC Therapeutics Limited's earnings per share (EPS)
What is PYC Therapeutics Limited's earnings per share (EPS)?
PYC Therapeutics Limited's earnings per share (EPS) over the last twelve months is $-0.04, as of Jun 2026.
What was PYC Therapeutics Limited's earnings per share (EPS) in 2025?
In 2025, PYC Therapeutics Limited's earnings per share (EPS) was $-0.07, compared with $-0.01 in 2024.
How has PYC Therapeutics Limited's earnings per share (EPS) changed since 2020?
From 2020 to 2025, PYC Therapeutics Limited's earnings per share (EPS) was highest in 2023 (0.00) and lowest in 2025 ($-0.07).
How does PYC Therapeutics Limited's earnings per share (EPS) compare with similar companies?
PYC Therapeutics Limited's earnings per share (EPS) ($-0.04) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.